Enleofen announce breakthrough in the treatment of fibrosis
Our client Enleofen has announced a breakthrough discovery in the treatment of fibrosis. The groundbreaking research, published in Nature, demonstrates that interleukin 11 (IL-11) is a key mediator of fibrosis in tissues including the heart and kidney. The importance of IL-11 has previously been overlooked as studies have focused on Transforming Growth Factor β1 (TGFβ1).
The research led by Stuart Cook and Sebastian Schäfer, co-founders of Enleofen, was performed by a team of scientists at Duke-NUS Medical School and the National Heart Centre Singapore. Enleofen are a biotechnology company based in Singapore, developing first-in-class therapeutics for the treatment of fibrotic human diseases.